Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential. Broadens development pipeline with an adenovirus 4/7 vaccine funded...
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and six months ended June 30,...
Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1 clinical study to evaluate the safety and pharmacokinetics of ZIKV-IG, the company’s anti-Zika virus immune...
Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 2, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2018, recent...
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate overview and discuss recent business developments during a...
Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
Emergent BioSolutions Inc. (NYSE:EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finish facility located in Baltimore, Md. The multi-year expansion is...
CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE:EBS) under which Profectus and...
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 24, 2018 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian...
Emergent BioSolutions Reports First Quarter 2018 Financial Results
Reaffirms full year 2018 financial forecast and operational goals. Provides Q2 2018 revenue forecast of $205M-$230M. Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter...
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2018, recent business...
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorisation of BioThrax® (Anthrax Vaccine Adsorbed) in five...
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
Emergent BioSolutions Inc. (NYSE:EBS) today announced executive management changes that continue to align its organizational structure to its long-term strategy and to the achievement of its near-...